Extremely good it reinforces the appeal from the market for this sector.
LBT has a mrkt cap of circa $120M and I don't believe their tech has the same widespread appeal or ease of marketing to understand what it is to joe public and funds , so I think epat can exceed their performance
Of course this is not all straight away it will be a journey but a lot of these stocks are demonstrating that pullbacks are met with buying and new highs , if you sell things like LBT , RAP and MEB and go away for a while you might not get back in cheaper
The other encouragement is epat milestone table with commercialisation within the next 12 months this means regulatory approval might happen sooner than what people think. Testing is already underway
LBT also shows that with no volume prior to the approval news these annuncement can happen without warning so spending more time out of the market is a risk to holding the stock and letting the story unfold
- Forums
- ASX - By Stock
- Information on re-listing
Extremely good it reinforces the appeal from the market for this...
-
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MNQ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online